Exploring the efficacy of Ayurvedic interventions in managing Chronic Kidney Disease: A Pilot Study
Abstract
Introduction: Chronic Renal Failure (CKD) refers to a continual, irreversible reduction in nephron count. Identifying risk factors for CKD, even in those with normal GFR, is crucial factors include hypertension, diabetes, autoimmune issues, older age, African ancestry, family history of renal disease, previous acute renal failure, and indications like proteinuria or structural urinary tract irregularities. Materials and Methods: Study was conducted at the O.P.D. of Dept. of Kayachikitsa, State Ayurveda College & Hospital Lucknow. A total 34 patients were screened out of which 30 Patients meeting inclusion criteria were registered. The patient was given Gokshuradi Guggulu, Mutraghata Har Yoga (MGH Yoga) & Trina Panchmula Kwatha. Results: Out of 26 participants, 57.7% reported relief, 15.4% noted moderate improvement, and 7.7% reported mild improvement. Additionally, 19.2% stated no change, and none reported worsened health. These percentages indicate the intervention's potential effectiveness, with the majority experiencing relief. Discussion: Ayurvedic formulations, such as Trinpanchmool Kwath, Gokshuradi Guggulu, And MGH Yoga, exhibit promise in CKD management by addressing oxidative stress, diuretic action, and nephroprotective qualities.
Downloads
References
Walker BR, Colledge NR. Davidson's principles and practice of medicine e-book. Elsevier Health Sciences; 2013 Dec 6.
Guidelines – KDIGO [Internet]. Kdigo.org. 2016. Available from: https://kdigo.org/guidelines/
National Kidney Foundation. Kidney basics [Internet]. National Kidney Foundation. 2020. Available from: https://www.kidney.org/kidney-basics
Gaikwad, S.P. (2020) ‘Samprapti (Pathololgy of C.R.F) in Ayurvedic point of View’, in P.Y. Gaikwad (ed.) Chronic Renal Failure and Ayurveda. First. Chinchwadgoan, Pune: Manakarnika Publication, pp. 110.
Jayalakshmi S, Mishra A, Mishra A, Singla RK, Ghosh AK. In-vitro Evaluation of antioxidant activity of five drugs of Trinpanchmool. Pharmacologyonline. 2011 Jan 1;2:1153-9.
Dwivedi D, Mishra PK, Pandey AK. Management of chronic kidney disease through ayurveda: a case study.
Tripathi B, editor. Sharangdhara Samhita of Sharangdhara, Madhyam Khanda; Gokshuradiguggulu vatakkalpana. Ch. 7. Verses 84 87.Varanasi: Chawkhamba Subharti Prakashana; 2017
MuhammedS.V., SAMS, urinary system diseases, mutrakrchra & mutraghata chapter 1 Volume 1 third edition page no 393
Sharma, M. and Sahu, S. (2022) Gallery of medicinal plants: Dravyaguna Vigyan. Noida, Uttar Pradesh: THIEME
Sastry, J.L. (2018) ‘Kasni’, in T. m Nesari (ed.) A Textbook of Dravyaguna Vijnana. Varanasi, Uttar Pradesh: Chaukhambha Orientalia, p410
Sastry, J.L. (2018) ‘Shigru’, in T. m Nesari (ed.) A Textbook of Dravyaguna Vijnana. Varanasi, Uttar Pradesh: Chaukhambha Orientalia, p272
Ravishankara MN, Shrivastava N, Padh H, Rajani M. Evaluation of antioxidant properties of root bark of Hemidesmus indicus R. Br.(Anantmul). Phytomedicine. 2002 Jan 1;9(2):153-60.
Shirwaikar A, Setty MM, Bommu P, Krishnanand B. Effect of lupeol isolated from Crataeva nurvala Buch.-Ham. stem bark extract against free radical induced nephrotoxicity in rats.
Jha, C. (2012) ‘Praval’, in Ayurvediya RasaShastra (A Textbook of Rasashastra). 2012th edn. Varanasi, Uttar Pradesh: Chaukhambha Surbharti, pp. 401–404.
Copyright (c) 2024 Abhishek Semwal, Sharad Johri, Amit Rajpoot
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Ayurveda and Integrated Medical Sciences (JAIMS) retains the copyright of the contents of this journal but grant the readers the right to use the contents with terms and conditions under a creative common attribution licenses 4 of Attribution, Share Alike and Non-commercial type (CC BY-NC-SA) that allows copy, distribute, display, and perform the work and make derivative works based on it only for non-commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.